Revolution Medicines (RVMD) EBITDA (2019 - 2026)

Revolution Medicines' EBITDA history runs 8 years deep, the most recent figure standing at -$445.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 84.92% year-over-year to -$445.2 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 84.96% YoY), while the FY2025 annual figure was -$1.1 billion, down 88.45% from the prior year.
• EBITDA was -$445.2 million for Q1 2026 at Revolution Medicines, down from -$364.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$57.9 million in Q1 2022 to a low of -$445.2 million in Q1 2026.
• Historically, EBITDA has averaged -$175.0 million across 5 years, with a median of -$150.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBITDA fell 16.62% in 2022, then plunged 159.49% in 2023.
• A 5-year view of EBITDA shows it stood at -$61.7 million in 2022, then slumped by 159.49% to -$160.1 million in 2023, then decreased by 23.07% to -$197.1 million in 2024, then tumbled by 85.11% to -$364.8 million in 2025, then dropped by 22.06% to -$445.2 million in 2026.
• The last three EBITDA figures came in at -$445.2 million (Q1 2026), -$364.8 million (Q4 2025), and -$303.4 million (Q3 2025), per Business Quant data.